Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

DuPont Merck reports pharmacokinetic data for novel gpIIb/IIIa antagonist

Dec. 13, 1996

Novel mechanism of action reported for Xenova PAI inhibitor

Dec. 13, 1996

Warfarin underused for stroke prevention

Dec. 11, 1996

Antithrombin III advances to phase II

Dec. 11, 1996

Allelix reports thrombospondin-derived antihemorrhagic peptide

Dec. 11, 1996

New thrombin inhibitors under study at Merck & Co.

Dec. 9, 1996

Vascular Therapeutics licenses Recordati compound

Dec. 4, 1996

Merck reveals new thrombin inhibitor series

Dec. 3, 1996

3DP seeks partners for protease inhibitor discovery program

Nov. 29, 1996

Merck & Co. reports nonpeptide fibrinogen antagonists with oral activity

Nov. 28, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...